Adaptimmune Therapeutics 2019 Annual Report 10-K

Adaptimmune Therapeutics plc's 2019 Form 10-K annual report detailing the company's SPEAR T-cell platform development, including pipeline candidates ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP. The filing discusses manufacturing capabilities, clinical development timelines, regulatory pathways, and key collaborations with GSK and Astellas.